Maryna C Eichelberger


Affiliation: Food and Drug Administration
Country: USA


  1. request reprint
    Eichelberger M, Bauchiero S, Point D, Richter B, Prince G, Schuman R. Distinct cellular immune responses following primary and secondary influenza virus challenge in cotton rats. Cell Immunol. 2006;243:67-74 pubmed
    ..These studies are the first to show evidence of a memory T cell response to influenza infection in cotton rats and show quantitative and qualitative differences between the recall response to homosubtypic and heterosubtypic viruses. ..
  2. Jiang L, Fantoni G, Couzens L, Gao J, Plant E, Ye Z, et al. Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase. J Virol. 2016;90:117-28 pubmed publisher
    ..One of the tested MAbs, which binds to a conserved region in the NA of pH1N1 virus, inhibited NA activity but did not result in escape variants, highlighting its suitability for development as a therapeutic agent. ..
  3. Wang X, Ilyushina N, Lugovtsev V, Bovin N, Couzens L, Gao J, et al. Amino Acids in Hemagglutinin Antigenic Site B Determine Antigenic and Receptor Binding Differences between A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses. J Virol. 2017;91: pubmed publisher
    ..These amino acid mutations also alter binding to minor human-type glycans, suggesting that host adaptation may contribute to the selection of antigenically distinct H3N2 variants which pose a threat to public health. ..
  4. Gao J, Couzens L, Burke D, Wan H, Wilson P, Memoli M, et al. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies. MBio. 2019;10: pubmed publisher
  5. Eichelberger M, Hassantoufighi A, Wu M, Li M. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Virol J. 2008;5:109 pubmed publisher
    ..This assay is suitable for high throughput screening to identify potential antivirals or can be used to identify drug-resistant influenza strains. ..
  6. Eichelberger M, Morens D, Taubenberger J. Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness. Curr Opin Immunol. 2018;53:38-44 pubmed publisher
    ..This suggests NA may be a good choice for inclusion in universal influenza vaccines. ..
  7. Couzens L, Gao J, Westgeest K, Sandbulte M, Lugovtsev V, Fouchier R, et al. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Methods. 2014;210:7-14 pubmed publisher
    ..The ELLA described in this report provides a practical format for routine evaluation of human antibody responses to NA. ..
  8. Eichelberger M, Couzens L, Gao Y, Levine M, Katz J, Wagner R, et al. Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity. Vaccine. 2016;34:458-465 pubmed publisher
    ..This study identified background signal and the amount of antigen in the assay as critical factors that influence titer, providing important information toward development of a consensus ELLA protocol. ..
  9. Gao J, Couzens L, Eichelberger M. Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay. J Vis Exp. 2016;: pubmed publisher
    ..The ELLA provides a practical format for routine evaluation of human antibody responses following influenza infection or vaccination. ..

More Information


  1. Wan H, Sultana I, Couzens L, Mindaye S, Eichelberger M. Assessment of influenza A neuraminidase (subtype N1) potency by ELISA. J Virol Methods. 2017;244:23-28 pubmed publisher
    ..The ELISAs we describe may expedite the development of NA-based influenza vaccines by providing a practical assay to measure NA potency. ..
  2. Wan H, Qi L, Gao J, Couzens L, Jiang L, Gao Y, et al. Comparison of the Efficacy of N9 Neuraminidase-Specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection. J Virol. 2018;92: pubmed publisher
    ..This study identifies in vitro measures that can be used to predict the in vivo efficacy of NA-specific antibodies, providing a way to select MAbs for further therapeutic development. ..